NEW YORK, March 25, 2015 /PRNewswire/ -- S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on Abattis Bioceuticals Corp.

Abattis Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company seeks to capitalize on the current trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. Abattis also has an extensive pipeline of products and intellectual property for the botanical drug market.

Abattis' intellectual property and activities encompass cannabis cultivation, production, extraction and refining technologies, quality control and laboratory analysis services, patient payment technologies and several derivative products.

The company specializes in a number of areas, including medical marijuana, cannabis cultivation, marijuana dispensary payment system, high yield marijuana growing, quality control testing 502, refined marijuana CBD oil, THC extract oil, CBD extract oil, CBD extraction equipment, CO2 super critical, cannabinoid extracts, butane honey oil extracts, licensed producer, pre-paid patient card, medical marijuana phone app, and controlled cultivation environment.

Abattis owns several subsidiaries with varying capabilities.

Biocube Green Grow Systems Corp., a wholly owned subsidiary of Abattis, provides controlled cannabis cultivation environments for high yield marijuana growing. Biocube has exclusive worldwide rights to a building product derived from magnesium oxide known as MgO board, which has applications in all areas of the building and construction industry as a fireproof, antimicrobial, antibacterial, waterproof, and recyclable material.

iJuana Cannabis Inc., a wholly owned subsidiary of Abattis, aims to become the licensed cannabis growing arm and consumer-facing entity for the company.

BioCell Labs Inc., another wholly owned subsidiary of Abattis, is focused on supplying standardized pharmaceutical grade products. BioCell leases a botanical drug facility that it will use to perform quality testing and refining using its proprietary Flash Freeze Extraction (FFE) and water extraction technologies. It has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.

North American BioExtracts Inc., the wholly owned retail distribution arm of Abattis, operates in Canada and Washington State. It will focus on cannabis, cannabis derivatives, and ancillary products like vaporizers where legally permitted. The subsidiary aims to use its proprietary extraction technologies to develop customized THC extract oils and CBD extract oils, as well as customized vaporizer flavors to enhance the end user's experience.

Northern Vine Canada Inc. has applied for a Controlled Substance License with Health Canada, with an existing cannabis processing, testing, and packaging facility located in Langley, British Columbia. In addition to these services, Northern Vine will support its operations by providing analytical services for licensed producers and charging a fee to produce a certificate of analysis. The firm will also formulate compositions for sprays, creams, and tinctures that it plans to patent.

On May 21, 2014, Abattis had leased a 16,200-square-foot facility zoned for medical marijuana near Vancouver, British Columbia with the potential to expand to up to 254,000 square feet. On February 21, 2014, Biocube acquired the Exclusive World Wide Distribution Rights to Jiangsu Jiahui New Material Co Ltd.'s innovative MgO (Magnesium Oxide) products for use in any building or facility designed to cultivate botanicals. The term of the exclusivity is 5 years. On March 31, 2014, the company incorporated a wholly owned subsidiary Abattis Bioceuticals International Inc. in the United States. On March 12, 2014, Abattis sent its newly designed Biocube drawings to China to have its first order produced.

On January 16, 2014, the company was added to The Marijuana Index™. The Index's website, mmj-index.com, states: This is the first and only registered equity tracking index which monitors the performance, news and general pulse of qualified marijuana stocks or cannabis stocks.

S&P Capital IQ's Factual Stock Report coverage on Abattis Bioceuticals Corp will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.abattis.com/ for additional information.

About S&P Capital IQ's Factual Stock Reports

Currently profiling approximately 400 issuers, S&P Capital IQ (MHFI) Factual Stock Reports increase market awareness of issuers in the investment community with insightful commentary, key statistics, and relevant corporate information.  The Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information on the covered companies to reach a wide spectrum of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the Reports also capture recent company developments, a financial review, key operating information, industry and peer comparisons, Street Consensus, performance charts, business summary, fundamental data, and timely news stories. Coverage of these reports is underwritten by the issuer, therefore S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

S&P Capital IQ Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations.  S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial (NYSE:MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need.  For more information, visit www.spcapitaliq.com.

In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies.

SOURCE S&P Capital IQ